Project description:CNN2 is identified as a tumor promotor in the development of colorectal cancer. Herein, gene expression in RKO cells infected with shCtrl and shCNN2 (for CNN2 knockdown) was detected with a Clariom S array. Gene expression profiling of shCtrl and shCNN2 RKO cells was acquired and analyzed. Differentially expressed genes were identified based on fold change of mean of expression (fold change ≥ 1.3) and FDR (< 0.05) from P value calculated based on linear model of empirical Bayesian distribution. In total, 523 upregulated genes and 648 downregulated genes were characterized.
Project description:Experiment description to give context to the data set: Ductal carcinoma in situ (DCIS), the most common type of pre-invasive lesion of breast, is being detected with increasing frequency with the advent of mammographic screening. Surgery is the mainstay for the treatment of DCIS. Based on the clinic-pathological features of DCIS, this may be followed by radiotherapy and/or endocrine therapy. The qualitative assessment of histological grade, expression of single protein biomarkers and more recently, mRNA analysis (DCIS Score) have been used to make these decisions. However, these factors do not fully predict the likelihood of development of invasive breast cancer treated with breast-conserving surgery. A majority of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then face a risk of development of invasive breast cancer. Using Human Clariom D Pico Assay, we aim to compare the transcriptome profiles of DCIS in relation to development of invasive breast cancer (INV-BC) versus Non-INV-BC cases. Experimental Methods Clariom D Pico Human Transcriptome Array were performed according to Applied Biosystems/Thermo Fisher Scientific’s instructions. Experimental protocols are summarized in detail in Supplementary Methods (Supplementary Data). Sample annotation We compared the relative gene expression in development of invasive breast cancer (INV-BC) versus Non-INV-BC cases in Singapore cohort-59 cases (discovery cohort) and Italian cohort-50 cases (validation cohort). Microplate Plate and Well IDs are also provided as Clariom D ID list per cohort. Author information Dr. Sunil Badve is the Principal Investigator. Raw Data Probe Cell Intensity (CELL) and .ARR files which contain the design information for this study are provided (Human Clariom D Pico Assay).
Project description:GABRD is identified as a tumor promotor in the development of gastric cancer. Herein, to further explore the downstream regulated genes involved in GABRD mediated tumor progression, an Affymetrix Clariom S human Assay was performed to profile the expression of GABRD regulated genes in AGS cells. Gene expression profiling of shCtrl and shGABRD AGS cells was acquired and analyzed. Differentially expressed genes were identified based on fold change of mean of expression (fold change ≥ 1.5) and FDR (< 0.05) from P value calculated based on linear model of empirical Bayesian distribution. GABRD expression regulated the expression of 2644 genes in AGS cells, of which 1199 were upregulated and 1445 were downregulated upon GABRD silencing.
